Proviruses

• 

  Subject Areas on Research

  • A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. 
  • AIDS. Where has HIV been hiding? 
  • Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. 
  • Activation of tat-defective human immunodeficiency virus by ultraviolet light. 
  • Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. 
  • Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. 
  • Amplification of HIV-1 provirus from cerebrospinal fluid and its correlation with neurologic disease. 
  • Amplification of human immunodeficiency virus provirus from cerebrospinal fluid: results of long-term clinical follow-up. 
  • Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences. 
  • Derivation of a biologically contained replication system for human immunodeficiency virus type 1. 
  • Detection of HIV-2 by PCR. 
  • Development and characterization of an Fv-1-sensitive retrovirus-packaging system: single-hit titration kinetics observed in restrictive cells. 
  • Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. 
  • Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. 
  • Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. 
  • Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6). 
  • Gonococcal lipooligosaccharide suppresses HIV infection in human primary macrophages through induction of innate immunity. 
  • Group II introns designed to insert into therapeutically relevant DNA target sites in human cells. 
  • HIV reservoirs: the new frontier. 
  • HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. 
  • HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. 
  • High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. 
  • Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation. 
  • Human topoisomerase I promotes HIV-1 proviral DNA synthesis: implications for the species specificity and cellular tropism of HIV-1 infection. 
  • Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. 
  • Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. 
  • Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. 
  • Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. 
  • Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. 
  • Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins. 
  • Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. 
  • Insights into the mechanisms underlying the inactivation of HIV-1 proviruses by CRISPR/Cas. 
  • Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. 
  • Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. 
  • Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. 
  • Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. 
  • Patterns of HIV-1 mRNA expression in transgenic mice are tissue-dependent. 
  • Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. 
  • Reduction of peak viremia by an integration-defective SIV proviral DNA vaccine in rhesus macaques. 
  • Regulation of human immunodeficiency virus replication. 
  • Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity. 
  • Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. 
  • The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro. 
  • Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV. 
  • Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. 
• 

  Keywords of People

  • Cunningham, Coleen Kathryn, Adjunct Professor in the Department of Pediatrics, Pediatrics